

Title (en)  
ANTICANCER COMPOSITIONS

Title (de)  
ANTIKREBSZUSAMMENSETZUNGEN

Title (fr)  
COMPOSITIONS ANTI-CANCÉREUSES

Publication  
**EP 3226841 A1 20171011 (EN)**

Application  
**EP 15817641 A 20151203**

Priority  
• EP 14196594 A 20141205  
• US 2015063661 W 20151203

Abstract (en)  
[origin: WO2016090098A1] The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naïve metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent.

IPC 8 full level  
**A61K 9/14** (2006.01); **A61K 9/20** (2006.01)

CPC (source: CN EP IL KR US)  
**A61K 9/0053** (2013.01 - IL KR US); **A61K 9/141** (2013.01 - EP IL US); **A61K 9/146** (2013.01 - CN IL KR); **A61K 9/16** (2013.01 - IL US); **A61K 9/1652** (2013.01 - CN IL US); **A61K 9/1682** (2013.01 - IL US); **A61K 9/2054** (2013.01 - CN EP IL KR US); **A61K 9/2077** (2013.01 - CN IL US); **A61K 31/4184** (2013.01 - EP IL US); **A61K 31/4439** (2013.01 - IL KR); **A61K 31/444** (2013.01 - CN IL); **A61P 35/00** (2018.01 - EP IL)

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**WO 2016090098 A1 20160609**; AR 102926 A1 20170405; AU 2015358490 A1 20170608; AU 2015358490 B2 20210408; AU 2021201979 A1 20210429; AU 2021201979 B2 20230202; AU 2023202710 A1 20230518; BR 112017011788 A2 20171226; CA 2969656 A1 20160609; CL 2017001371 A1 20180105; CN 106999431 A 20170801; CN 106999431 B 20220304; CN 114886852 A 20220812; CO 2017005572 A2 20170920; CR 20170216 A 20170830; EA 201791222 A1 20170929; EP 3226841 A1 20171011; IL 252323 A0 20170731; IL 252323 B 20210429; IL 279833 A 20210131; IL 279833 B 20220301; JP 2017536398 A 20171207; JP 2020143069 A 20200910; JP 6937692 B2 20210922; JP 7174006 B2 20221117; KR 102348320 B1 20220110; KR 20170086656 A 20170726; KR 20200141533 A 20201218; MA 41107 A 20171010; MX 2017007203 A 20170828; MX 2021013965 A 20220104; NZ 731963 A 20240322; NZ 770528 A 20240322; PH 12017500964 A1 20171018; SG 11201704267V A 20170629; TW 201630592 A 20160901; TW 202031248 A 20200901; TW I702966 B 20200901; TW I754258 B 20220201; UA 120950 C2 20200310; US 2017360754 A1 20171221; US 2023233529 A1 20230727

DOCDB simple family (application)  
**US 2015063661 W 20151203**; AR P150103982 A 20151204; AU 2015358490 A 20151203; AU 2021201979 A 20210330; AU 2023202710 A 20230502; BR 112017011788 A 20151203; CA 2969656 A 20151203; CL 2017001371 A 20170529; CN 201580066233 A 20151203; CN 202210133724 A 20151203; CO 2017005572 A 20170605; CR 20170216 A 20151203; EA 201791222 A 20151203; EP 15817641 A 20151203; IL 25232317 A 20170516; IL 27983320 A 20201229; JP 2017529604 A 20151203; JP 2020076516 A 20200423; KR 20177018239 A 20151203; KR 20207035390 A 20151203; MA 41107 A 20151202; MX 2017007203 A 20151203; MX 2021013965 A 20170605; NZ 73196315 A 20151203; NZ 77052815 A 20151203; PH 12017500964 A 20170525; SG 11201704267V A 20151203; TW 104140822 A 20151204; TW 109112959 A 20151204; UA A201707020 A 20151203; US 201515533188 A 20151203; US 202318192244 A 20230329